Schildwächterlymphknotenexzision (SLKE) und Positronenemissionstomographie (PET)

Axel Schäfer(University of Applied Sciences and Arts Hildesheim/Holzminden/Göttingen), Peter J. Frosch(Ospedale Regionale di Bellinzona e Valli), Rudolf Herbst(Helios Klinikum Erfurt), B. Theophil(Klinik und Poliklinik für Nuklearmedizin), H. Treckmann(Klinikum Dortmund), S. Lange-Ionescu(Witten/Herdecke University), Ulrike Beiteke, D. Löhlein(Klinikum Dortmund), Hans‐Jochen Bartels(Praxis), E.‐W. Schwarze(Klinikum Dortmund), G. Thiemann(Klinik und Poliklinik für Nuklearmedizin)

Der Hautarzt

January 15, 2003

10.1007/s00105-002-0453-6

Cited by 13

Related Papers

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

|The Lancet Oncology|2016|704

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

|PLoS ONE|2015|292

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node

|Journal of Clinical Oncology|2019|254

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

|The Lancet|2020|242

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

|European Journal of Cancer|2017|203